NGM282 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	2
94	Primary sclerosing cholangitis	3

93. Primary biliary cholangitis

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02135536 (ClinicalTrials.gov)	May 2014	8/5/2014	Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis	A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282Administered for 24 Weeks in Patients ...	Primary Biliary Cirrhosis	Biological: NGM282	NGM Biopharmaceuticals, Inc	NGM Biopharmaceuticals Australia Pty Ltd	Completed	18 Years	75 Years	All	36	Phase 2	United States;Australia;New Zealand
2	NCT02026401 (ClinicalTrials.gov)	February 2014	30/12/2013	Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis	A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Ev ...	Primary Biliary Cirrhosis	Biological: NGM282;Biological: Placebo	NGM Biopharmaceuticals, Inc	NGM Biopharmaceuticals Australia Pty Ltd	Completed	18 Years	75 Years	All	45	Phase 2	United States;Australia

First Previous1Next Last

94. Primary sclerosing cholangitis

Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003392-30-NL (EUCTR)	02/05/2016	17/12/2015	The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC)	A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EV ...	PRIMARY SCLEROSING CHOLANGITIS (PSC) MedDRA version: 19.0;Level: LLT;Classification code 10036732;Te ...	Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: r ...	NGM Biopharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	France;United States;Netherlands;United Kingdom
2	EUCTR2015-003392-30-GB (EUCTR)	18/04/2016	14/12/2015	The testing of NGM282 for 12 weeks in patients with Primary Sclerosing Cholangitis (PSC)	A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EV ...	PRIMARY SCLEROSING CHOLANGITIS (PSC) MedDRA version: 19.0;Level: LLT;Classification code 10036732;Te ...	Product Name: NGM282 INN or Proposed INN: engineered recombinant human FGF19 Other descriptive name: r ...	NGM Biopharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;United States;Netherlands;United Kingdom
3	NCT02704364 (ClinicalTrials.gov)	March 2016	29/2/2016	Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis	A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Ev ...	Primary Sclerosing Cholangitis	Biological: NGM282;Other: Placebo	NGM Biopharmaceuticals, Inc	NULL	Completed	18 Years	75 Years	All	62	Phase 2	United States;France;Netherlands;United Kingdom

First Previous1Next Last